Layer 1

EMIS: Prescribers can select levothyroxine brands for fair EPS payment

Exclusive
EMIS: EMIS Web supports the prescribing of levothyroxine generically or via brand
EMIS: EMIS Web supports the prescribing of levothyroxine generically or via brand

Prescribers can specify a particular generic manufacturer for EPS reimbursement purposes, EMIS has told C+D, avoiding pharmacies losing out fulfilling more expensive prescriptions.

Concerns had been raised following new Medicines and Healthcare products Regulation Agency (MHRA) advice on levothyroxine that prescribers were not able to stipulate a specific manufacturer in the ‘drug line’ field on electronic prescriptions, which is read by the NHS Business Services Authority (NHS BSA) reimbursement system.

This could lead to pharmacists receiving prescriptions for medicines with the manufacturer in the ‘free text’ box instead, which cannot be read by the NHS BSA system and may cost more than the generic tariff contractors would subsequently be reimbursed for.

Dr Shaun O’Hanlon, chief medical officer at the EMIS Group – whose software is used by 57% of GP practices in the UK – confirmed to C+D that their clinical system EMIS Web “supports the prescribing of levothyroxine generically or via brand as per the dm+d”, (the NHS dictionary of medicines and devices).

A spokesperson for the EMIS Group added it would “welcome clarification from the relevant NHS authorities” on “how GP prescribing systems should manage this issue for EPS prescriptions”.

While EMIS Web has the functionality, some prescribers have told C+D that the manufacturer does not appear on the final EPS.

C+D has asked the EMIS Group to clarify.  

How the NHS BSA system works

As reported by C+D last week (May 26), an MHRA guidance update on levothyroxine said prescribers should “consider consistently prescribing a specific levothyroxine product known to be well tolerated by the patient…if a patient is persistently symptomatic after switching levothyroxine products”.

This includes “switching between different generic brands”, it told C+D. However, there was concern that this would lead to contractors losing out in cases where the prescriber only enters the generic – rather than the specific manufacturer – in the ‘drug line’ of the EPS.

According to the NHS BSA, prescribers can generate an electronic prescription service (EPS) prescription by selecting either a generically prescribed product (VMP) or for a specific brand or supplier (AMP).

C+D understands that the processing of electronic prescriptions is automated using concept IDs from dm+d, based on SNOMED, which is a clinical language that facilitates electronic communication between healthcare professionals.

An NHS BSA spokesperson told C+D: “If a prescriber issues an EPS prescription for a specific brand or supplier, we would receive the AMP SNOMED code as the prescribed product and would therefore reimburse the dispensing contractor based on that prescribed product.”

For the purposes of reimbursement, NHS BSA is only able to extract prescription data from the relevant fields, which do not include the ‘free text’ fields of the electronic prescription.

C+D understands that there are technical and information governance reasons for this and it is something that NHS BSA cannot change.

5 Comments
Question: 
Have you been affected by this issue?

Adam Hall, Community pharmacist

I find telling the patient "I'm sorry but the government won't pay for that particular brand" is a pretty good answer

Sean Whelan, Information Technology

Shouldn't DoH just remove the levothyroxine lines from Part 8a and then pharmacies are required to endorse the brand/manufacturer provided (plus price if needed). Solves itself then....

M. Rx(n), Student

This should happen automatically, with the RP appending their details for audit purposes.

I do not quite understand the bureaucracy here. Of course there's always the room for abuse, but it shouldn't blight efficiency.

V K P, Community pharmacist

will the NHSBSA inform the prescribers that it is their responsibility to address the manufcaturer criteria with their patients at the point of prescribing? Furthermore, will NHS educate and empower its patients of taking up their bespoke medicine requirements with their GP and not the pharmacy. The dispensing will be based on what is prescribed. Negotiations at the point of dispensing should be refrained from by the patient. 

M. Rx(n), Student

Better yet, NOMINAL GUARANTEED PAYMENT for the PHARMACIST actually doing their job should be sought by the PSNC!

Abdication of our PHARMACEUTICAL DUTIES does not gain us any leverage given the sequence of the care pathway.

Job of the week

Pharmacist Manager
Midlands, Cheshire & Dorset
Salary dependent upon experience